Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, Sagimet Biosciences Inc increased its cash reserves by 47,456.33%, or 74.98m. Cash Flow from Financing totalled 86.17m or 4,308.35% of revenues. In addition the company used 23.77m for operations while cash from investing totalled 12.58m.
Cash flow per share | -1.14 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 5.74 |
---|---|
Tangible book value per share | 5.74 |
More ▼
Balance sheet in USDView more
Current ratio | 29.11 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼